Amgen, Inc. (NASDAQ:AMGN) ATS and the Approval of IMDELLTRA Conference Call May 20, 2024 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - Executive Vice President, Global Commercial Operations James Bradner - Executive Vice President, Research and Development Jean-Charles Soria - Senior Vice President, Global Development Oncology Susan Sweeney - Senior Vice President, Global Marketing, Access Capabilities Primal Kaur - Vice President, Global Development, In ...

Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn’t mean much if you don’t have health. Therefore, this compelling subcategory of the broader healthcare market deserves attention.In addition, while the market has been robust – with the Dow Jones Industrial Average breaching the 40,000-point level – many concerns exist. Inflation remains elevated as are borrowing costs. Delinquency rates are ...

Eli Lilly's biggest growth drivers today are its weight loss drugs.Eli Lilly (LLY -0.14%) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight loss: Mounjaro and Zepbound. They're both based on the same molecule, but regulators approved the product for type 2 diabetes under the name Mounjaro and specifically for weight management under the name Zepbound.The company won approval for Mounj ...

Amgen (AMGN) announced that the FDA has granted accelerated approval to tarlatamab for pre-treated advanced small cell lung cancer (ES-SCLC).Tarlatamab is a delta-like ligand 3 targeting Bispecific T-cell Engager (BiTE) therapy, approved by the name of Imdelltra to treat ES-SCLC patients whose disease has progressed on or after treatment with platinum-based chemotherapy.The approval comes a month ahead of the PDUFA date on Jun 12. With the approval, Imdelltra becomes the first DLL3-targeting BiTE therapy th ...

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult ...

flying white dove isolated on black backgroundgettyRemember when the Federal Reserve stopped printing money for a few months? It didn’t go well.Yes, I’m making fun. A bit. Chairman Jay Powell did abstain from his printing press for nine full months.The year, as you’ll recall, was 2022. Headline inflation topped 8%. Eight! Jay, who had been blaming every supply chain from here to Shanghai for the price pressures, ran out of excuses. He held down the power button on his money printer for a hard reset.Stocks s ...

THOUSAND OAKS, Calif., May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice presiden ...

Summary of Amgen Inc. Conference Call Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Event**: BofA Securities 2024 Health Care Conference - **Date**: May 14, 2024 Key Points Industry and Market Dynamics - Amgen is focusing on expanding its manufacturing capacity to support both clinical and commercial supply, particularly for its obesity-related drug, MariTide [3][24] - The company is committed to addressing the global health crisis of obesity and sees it as a platform for long-term growth [20][21] Product Performance - **Repatha**: Sales increased by 33% in Q1, with a 44% growth in volume. The company is optimistic about its future, especially with the upcoming VESALIUS trial for primary prevention in high-risk cardiovascular patients [4][36] - **TEZSPIRE**: The company is seeing growth in the rare disease segment, with TEPEZZA showing a 5% growth in Q1. Amgen plans to expand its market penetration and is focusing on low CAS patients [40][41] - **Rare Disease Portfolio**: Contributed nearly $1 billion in sales, up 14% year-over-year. Products like KRYSTEXXA and UPLIZNA are performing well, with UPLIZNA up 59% [5][42] Pipeline and Future Developments - Amgen is advancing a robust pipeline, including promising new medicines in various therapeutic areas. The company is particularly excited about tarlatamab, a bispecific antibody for small cell lung carcinoma, with a PDUFA date set for June 12, 2024 [6][46] - MariTide is in Phase II trials, with plans for a broad Phase III program. The company is confident in its differentiated profile compared to existing treatments [3][10][13] Manufacturing and Capacity Expansion - Amgen is investing significantly in manufacturing capabilities, including a new fill-and-finish plant in Ohio and a drug substance plant in North Carolina, set to open in 2026 [25][26] - The company emphasizes its readiness to meet patient demand and is committed to optimizing its global manufacturing network [26] Competitive Landscape - Amgen acknowledges the competitive landscape in obesity treatments but believes its long-standing expertise in metabolism and human genome science gives it an edge [11][19] - The company is also exploring various mechanisms of action for obesity treatments, indicating a commitment to innovation in this area [21][30] Strategic Focus - Amgen is open to evaluating potential acquisitions or collaborations, particularly in the rare disease space, while maintaining a focus on deleveraging in the coming years [44][45] - The company aims to leverage its strengths in discovery research and manufacturing to enhance its product offerings and market presence [44] Conclusion - Amgen is positioned for long-term growth through its diverse therapeutic areas, strong product performance, and commitment to innovation in addressing significant health challenges like obesity and rare diseases [3][20][21]

17 November 2023, Berlin: View of a screen with the lettering Lilly Deutschland GmbHì. The US ... [+] pharmaceutical company Eli Lilly announced investment plans in Germany at the press conference. Photo: Hannes P. Albert/dpa (Photo by Hannes P Albert/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesGiven its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus ...

The biotech's pipeline extends far beyond this exciting weight-loss product.It's a race to the riches in the anti-obesity drug market. This therapeutic area is projected to grow exponentially in the coming years. Novo Nordisk is one of the clear market leaders -- for now -- thanks to its now-famous therapy, Wegovy. However, several companies have promising pipeline candidates they hope will eventually challenge Wegovy.One of them is Amgen (AMGN -0.87%), one of the largest biotechs in the world. Amgen recent ...